Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 1998

View Archived Issues

Recent infection: an independent risk factor for acute cerebrovascular ischemia

MKC-231: a neuroprotective agent with choline uptake and acetylcholine-releasing properties

Site of spatial short-term memory at last identified in the human brain

Metadoxine is beneficial in alcoholic patients, even with continued alcohol consumption

Yamanouchi research yields potential new antipsychotic agents

Sumitomo scientists describe new agents for hyperlipidemia

Screening for the BRCA1 mutation is not beneficial in the general female population

Bosentan reduces blood pressure in patients with essential hypertension

FDA okays protocol amendments for phase III trial of CBP-1011

SciClone receives approval to market Zadaxin for hepatitis B in Kuwait

FDA advisory committee recommends expanded labeling for CEPRATE SC System

Northwest Hospital's prostate cancer vaccine shows promise in phase I/II; new trial sites added

Company Profile: Afferon

Company Profile: Hexagen

New mechanism identified for Fujisawa antiinflammatory agent

Differentiation-inducing retinoyloxy(substituted)alkylene butyrates from Bar-Ilan

Further mechanism-of-action studies conducted on T-614

Sankyo's kappa-opioid agonist demonstrates potent antinociceptive activity

Schering AG describes new diagnostics

Vacuolar ATPase inhibitors claimed by SmithKline Beecham for osteoporosis

HSR-609: a potent and insurmountable H1 antagonist in vitro

First report of nonpeptide compounds as MHC class II inhibitors

New treatments for preterm labor from Merck

IL-10 in clinical testing for multiple indications at Schering-Plough

TOBI now available for CF patients with P. aeruginosa

FDA decides future of pimagedine trials

FDA to review data from phase III trial of Alferon N Injection in HIV

Celecoxib copromotion agreement expanded

Glaxo Wellcome files for European approval of lamivudine in HBV